Clinical Arterial Peripheral Vascular Pathology Does Not Impact Short- or Long-Term Survival after Transcatheter Aortic Valve Replacement
Table 4
Vascular Pathology
Control
P-value
Survival > 1 month
94 (138/147)
95 (186/195)
.812
Survival > 6 month
88 (102/116)
89 (142/159)
.847
Survival > 1 year
74 (69/93)
83 (110/132)
.130
Survival > 2 year
58 (37/64)
63 (52/83)
.611
Periprocedural Major Vascular
10 (14)
8 (15)
.561
Periprocedural Minor Vascular
10 (15)
8 (15)
.443
Post-TAVR PPM implantation
8 (12)
8 (16)
1.000
Periprocedural Increase in Serum Creatinine >1.5x baseline
8 (12)
4 (7)
.093
In Hospital CV Mortality
6 (9)
6 (11)
.821
In Hospital MI
0 (0)
1 (2)
.509
In Hospital Stroke/TIA
2 (3)
3 (6)
.738
In Hospital HF exacerbation
24 (35)
19 (38)
.352
Discharge to 30 days MACCE
18 (24)
18 (33)
1.000
Discharge to 30 days CV Mortality
0 (0)
1 (1)
1.000
Discharge to 30 days Myocardial Infraction
1 (1)
1 (2)
1.000
Discharge to 30 days Stroke/TIA
1 (1)
1 (2)
1.000
Discharge to 30 days HF exacerbation
17 (23)
15 (28)
.758
Discharge to 30 days Rehospitalization For Any Reason
17 (23)
18 (33)
.882
30 days- 6 months MACCE
31 (32)
25 (37)
.389
30 days- 6 months CV Mortality
2 (2)
2 (3)
1.000
30 days- 6 months Myocardial Infraction
2 (2)
1 (2)
1.000
30 days- 6 months Stroke/TIA
3 (3)
2 (3)
.694
30 days- 6 months HF exacerbation
17 (18)
14 (20)
.477
30 days- 6 months Rehospitalization For Any Reason
28 (29)
22 (33)
.373
6 months-1 year MACCE
40 (30)
24 (26)
.033
6 months-1 year CV Mortality
5 (4)
0 (0)
.028
6 months-1 year Myocardial Infraction
5 (4)
0 (0)
.028
6 months-1 year Stroke/TIA
4 (3)
0 (0)
.069
6 months-1 year HF exacerbation
17 (13)
21 (22)
.703
6 months 1 year Rehospitalization For Any Reason
33 (25)
26 (24)
.240
Values are % (n). MACCE = major adverse cardiovascular and cerebrovascular events, defined as death from any cause, myocardial infarction, rehospitalization, and stroke
